NCT00696163View on ClinicalTrials.gov

Observational Study to Assess the Quality of Life and Clinical Outcomes in Subjects Using NovoMix® 30 for the Treatment of Diabetes

CompletedOBSERVATIONAL
Enrollment

24,975

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2009

Conditions
DiabetesDiabetes Mellitus, Type 2
Interventions
DRUG

biphasic insulin aspart 30

Being an observational study, dose of NovoMix 30 will be according to treating physician's discretion

Trial Locations (1)

560001

Novo Nordisk Investigational Site, Bangalore

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY